相似文献
1
Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?
Crit Care. 2014 Jun 27;18(3):229. doi: 10.1186/cc13949.
2
Epidemiology and prevention of carbapenem-resistant Enterobacteriaceae in the United States.
Expert Rev Anti Infect Ther. 2014 May;12(5):565-80. doi: 10.1586/14787210.2014.902306. Epub 2014 Mar 25.
3
The emerging threat from carbapenem-resistant enterobacteriaceae.
Nurs Womens Health. 2013 Dec;17(6):519-24. doi: 10.1111/1751-486X.12080.
4
The spread of carbapenem-resistant Enterobacteriaceae in South Africa: risk factors for acquisition and prevention.
S Afr Med J. 2012 May 10;102(7):599-601. doi: 10.7196/samj.5789.
5
Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities.
MMWR Morb Mortal Wkly Rep. 2009 Mar 20;58(10):256-60.
6
Carbapenem-resistant enterobacteriaceae: an emerging problem in children.
Clin Infect Dis. 2012 Sep;55(6):852-9. doi: 10.1093/cid/cis543. Epub 2012 Jun 14.
7
Factors Associated to Prevalence and Incidence of Carbapenem-Resistant Enterobacteriaceae Fecal Carriage: A Cohort Study in a Mexican Tertiary Care Hospital.
PLoS One. 2015 Oct 2;10(10):e0139883. doi: 10.1371/journal.pone.0139883. eCollection 2015.
8
Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae.
Diagn Microbiol Infect Dis. 2016 Jun;85(2):266-75. doi: 10.1016/j.diagmicrobio.2015.10.008. Epub 2015 Oct 14.
9
A Systematic Review and Meta-analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae.
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01730-17. Print 2018 Jan.
10
The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
J Assoc Physicians India. 2012 Aug;60:28-30.
引用本文的文献
1
Detection of and Antibiotic Resistance in Burn Wards in China From 2019 to 2023.
Infect Drug Resist. 2025 Mar 24;18:1595-1604. doi: 10.2147/IDR.S505514. eCollection 2025.
2
Mortality factors and antibiotic options in carbapenem-resistant Enterobacterales bloodstream infections: Insights from a high-prevalence setting with co-occurring NDM-1 and OXA-48.
Clin Transl Sci. 2024 Jun;17(6):e13855. doi: 10.1111/cts.13855.
3
Carbapenemase producing at a large teaching hospital in Ohio: comparison to state surveillance and retrospective analysis of patient characteristics.
Infect Prev Pract. 2024 Apr 27;6(2):100366. doi: 10.1016/j.infpip.2024.100366. eCollection 2024 Jun.
4
Emergence and genomic chion of Proteus mirabilis harboring bla in Korean companion dogs.
Vet Res. 2024 Apr 9;55(1):50. doi: 10.1186/s13567-024-01306-w.
5
The Effect of Double Carbapenem Regimen in the Management of Carbapenem-Resistant Klebsiella pneumoniae Infections: A Report of Five Cases.
Cureus. 2024 Jan 10;16(1):e52023. doi: 10.7759/cureus.52023. eCollection 2024 Jan.
6
Molecular characteristics and antimicrobial resistance profiles of Carbapenem-Resistant Klebsiella pneumoniae isolates at a tertiary hospital in Nanning, China.
BMC Microbiol. 2023 Oct 28;23(1):318. doi: 10.1186/s12866-023-03038-x.
7
Distribution and Antibiotic Resistance Characteristics of Bacteria Isolated from Blood Culture in a Teaching Hospital in Vietnam During 2014-2021.
Infect Drug Resist. 2023 Mar 23;16:1677-1692. doi: 10.2147/IDR.S402278. eCollection 2023.
8
Carriage of multidrug-resistant Gram-negative bacilli: duration and risk factors.
Eur J Clin Microbiol Infect Dis. 2023 May;42(5):631-638. doi: 10.1007/s10096-023-04581-1. Epub 2023 Mar 25.
9
Genomic epidemiological analysis of -harboring collected from livestock settings in Vietnam.
Front Vet Sci. 2022 Oct 26;9:1034610. doi: 10.3389/fvets.2022.1034610. eCollection 2022.
10
Identification of KPC-112 from an ST15 Klebsiella pneumoniae Strain Conferring Resistance to Ceftazidime-Avibactam.
mSphere. 2022 Dec 21;7(6):e0048722. doi: 10.1128/msphere.00487-22. Epub 2022 Nov 14.
本文引用的文献
1
Notes from the Field: New Delhi metallo-β-lactamase-producing Escherichia coli associated with endoscopic retrograde cholangiopancreatography - Illinois, 2013.
MMWR Morb Mortal Wkly Rep. 2014 Jan 3;62(51-52):1051.
2
Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
Int J Antimicrob Agents. 2014 Jan;43(1):52-9. doi: 10.1016/j.ijantimicag.2013.09.010. Epub 2013 Oct 16.
3
Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options.
Clin Microbiol Infect. 2014 Feb;20(2):O117-23. doi: 10.1111/1469-0691.12341. Epub 2013 Aug 30.
4
Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens.
Antimicrob Agents Chemother. 2013 Nov;57(11):5548-58. doi: 10.1128/AAC.01288-13. Epub 2013 Aug 26.
5
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.
Lancet Infect Dis. 2013 Sep;13(9):785-96. doi: 10.1016/S1473-3099(13)70190-7.
6
Detection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: recommendations from an International Working Group.
J Chemother. 2013 Jun;25(3):129-40. doi: 10.1179/1973947812Y.0000000062.
7
Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.
Clin Infect Dis. 2013 Aug;57(4):524-31. doi: 10.1093/cid/cit334. Epub 2013 May 22.
8
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America.
Clin Infect Dis. 2013 Jun;56(12):1685-94. doi: 10.1093/cid/cit152. Epub 2013 Apr 17.
9
Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae.
J Antimicrob Chemother. 2013 Aug;68(8):1825-31. doi: 10.1093/jac/dkt118. Epub 2013 Apr 10.
10
Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2013 Jun;57(6):2900-1. doi: 10.1128/AAC.00188-13. Epub 2013 Apr 9.
Zotero 插件